Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

In October 2023, bimekizumab was approved for moderate to severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy. 6 With the new indications ... naïve to biologic ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports ...

The three new nods stand to bolster the company ... Despite the hold-up, Bimzelx’s launch in psoriasis has been “the ...

Access to adequate care for psoriasis is inconsistent across Europe and the condition remains misunderstood and undertreated.

or the time from first conventional therapy to biologic therapy initiation in patients with psoriasis. Previous use of conventional systemic therapy does not significantly impact subsequent biologic ...

Psoriasis itself doesn't make you immunocompromised, however, medications that treat the condition can suppress the immune ...

Expected sometime in 2025, details on plans for enrollment by race, ethnicity, age, and sex will be required for all pivotal ...

Flakes won’t go away? You might be dealing with scalp psoriasis instead of dandruff! Here's how to know the difference ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...